Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.63 |
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24754417 | 0.84 | PARP1 (0.59) | PARP1PRMT5RXFP1HTR3AHTR4 | |
| SCHEMBL1477698 | 0.82 | PARP1 (0.69) | PARP1PRMT5RXFP1HTR3AHTR4 | |
| SCHEMBL2127143 | 0.81 | PARP1 (0.55) | PARP1PRMT5RXFP1HTR3AHTR4 | |
| SCHEMBL30848472 | 0.81 | PARP1 (0.55) | PARP1PRMT5RXFP1 | |
| SCHEMBL5480367 | 0.80 | PARP1 (0.66) | PARP1PRMT5RXFP1 | |
| SCHEMBL29698487 | 0.79 | PARP1 (0.64) | PARP1PRMT5RXFP1 | |
| SCHEMBL453514 | 0.78 | PARP1 (0.72) | PARP1RXFP1 | |
| Hydrochloric Acid SCHEMBL2129546 | 0.77 | PARP1 (0.70) | PARP1RXFP1 | |
| SCHEMBL9218238 | 0.77 | PARP1 (0.70) | PARP1RXFP1 | |
| Hydrochloric Acid SCHEMBL22165594 | 0.77 | PARP1 (0.70) | PARP1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039895-A1 | PROLYL HYDROXYLASE INHIBITORS | Glaxo Smith Kline LLC., a corporation | 2011-02-17 | — | — | US | claimed |
| EP-2273879-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2011-01-19 | — | — | EP | claimed |
| WO-2009134850-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-05 | — | — | WO | claimed |
| US-20110039895-A1 | PROLYL HYDROXYLASE INHIBITORS | Glaxo Smith Kline LLC., a corporation | 2011-02-17 | — | — | US | disclosed |
| US-20110039895-A1 | PROLYL HYDROXYLASE INHIBITORS | Glaxo Smith Kline LLC., a corporation | 2011-02-17 | — | — | US | disclosed |
| US-20110039895-A1 | PROLYL HYDROXYLASE INHIBITORS | Glaxo Smith Kline LLC., a corporation | 2011-02-17 | — | — | US | disclosed |
| EP-2273879-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009134850-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134850-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039895-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | EGLN1 6/4885PARP1 1606/4885PRMT5 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.